Advanced Nanomaterials to Target Genomic and Z-DNA for Bacterial Biofilm Eradication
Revolutionizing Antimicrobial Therapy: Advanced Nanomaterials to Eradicate Biofilms and Drug-Resistant Infections
BactEradiX vision is to pioneer a transformative solution in the fight against chronic infections and antimicrobial resistance, ensuring a healthier and safer future by eradicating biofilms and overcoming drug-resistant pathogens through groundbreaking nanotechnology.
Our mission is to develop a first-in-class, modular, and tunable antimicrobial nanoplatform leveraging innovative lipid-based nanocarriers and Z-DNA targeting technologies. BactEradiX focuses on delivering effective and biocompatible solutions to eradicate biofilms, eliminating multidrug-resistant bacteria, and providing sustainable tools to address global public health challenges posed by antimicrobial resistance.
Problem to be solved
Antimicrobial resistance (AMR) and chronic infections are critical global health threats, impacting millions of lives and jeopardizing medical advancements. Biofilm formation by bacteria is one of the main causes of treatment failure, infection recurrence, and acquired resistance development. These biofilms shield bacteria from conventional treatments, making infections increasingly difficult to eradicate.
With slowed antimicrobial development and rising drug-resistant bacteria like methicillin-resistant S. aureus (MRSA) and multidrug-resistant P. aeruginosa, the WHO identifies AMR as one of the top 10 public health threats facing humanity, underscoring the urgency of innovative strategies to address this escalating crisis.
Proposed Solution
BactEradiX offers an innovative, first-in-class approach to combat antimicrobial resistance and chronic infections by developing an advanced antimicrobial nanoplatform. This solution focuses on:
- Targeting Biofilm Z-DNA: Leveraging groundbreaking discoveries to destabilize biofilms, a major barrier to effective treatment.
- Cleaving Bacterial Genomic DNA: Using precision-designed artificial oligonucleotides to disrupt bacterial replication, leading to bacterial eradication.
- Lipid-Based Nanocarrier Technology: Employing modular, tunable lipid nanoparticles for targeted delivery, ensuring functionality and biocompatibility.
- WHO Priority Strains: Prioritizing the fight against methicillin-resistant S. aureus and multidrug-resistant P. aeruginosa.
By addressing biofilm-associated infections and drug-resistant pathogens, BactEradiX provides a scalable and sustainable platform to overcome the challenges of AMR and chronic infections.
Starting
1st December 2024
Duration
48 Months
Partners
8
Countries
3
Work packages
9
Funding
2.996.312,50 €
